Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome by Oberwahrenbrock, T et al.
  
Retinal ganglion cell and inner plexiform layer 
thinning in clinically isolated syndrome 
Timm Oberwahrenbrock1*, Marius Ringelstein2*, Simon Jentschke1, Katrin 
Deuschle1,3, Katharina Klumbies1, Judith Bellmann-Strobl1,3, Jens Harmel2, 
Klemens Ruprecht3, Sven Schippling4, Hans-Peter Hartung, MD2, Orhan 
Aktas, MD2, Alexander U. Brandt, MD1§ and Friedemann Paul, MD1,3§ 
1) NeuroCure Clinical Research Center and Experimental and Clinical Research 
Center, Charité University Medicine Berlin and Max Delbrück Center for 
Molecular Medicine, Berlin, Germany 
2) Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, 
Düsseldorf, Germany 
3) Department of Neurology, Charité University Medicine Berlin, Berlin, Germany 
4) Department of Neuroimmunology and Clinical Multiple Sclerosis Research, 
Neurology Clinic, University Medical Center Zurich, Zurich, Switzerland 
*) Equally contributing first authors in alphabetical order 
§) Equally contributing senior authors in alphabetical order 
Address for correspondence:  
Dr. Friedemann Paul, NeuroCure Clinical Research Center, Charité University 
Medicine Berlin, Charitéplatz 1, 10117 Berlin, Germany, Tel.: +49 30 450 539705, 
Fax +49 30 450 539915, Email: friedemann.paul@charite.de 
Keywords: clinically isolated syndrome, optical coherence tomography, retinal nerve 
fiber layer, retinal ganglion cell layer 
  
Abstract 
Background: Axonal and neuronal damage are widely accepted as key events in the 
disease course of multiple sclerosis. However, it has been unclear to date at which 
stage in disease evolution neurodegeneration begins and whether neuronal damage 
can occur even in the absence of acute inflammatory attacks. 
Objective: To characterize inner retinal layer changes in patients with clinically 
isolated syndrome (CIS). 
Method: 45 patients with CIS and age- and sex-matched healthy controls were 
investigated using spectral domain optical coherence tomography. Patients’ eyes 
were stratified into the following categories according to history of optic neuritis (ON): 
eyes with clinically diagnosed ON (CIS-ON), eyes with suspected subclinical ON 
(CIS-SON) as indicated by a visual evoked potential latency of >115ms and eyes 
unaffected by ON (CIS-NON). 
Results: CIS-NON eyes showed significant reduction of ganglion cell- and inner 
plexiform layer and a topography similar to that of CIS-ON eyes. Seven eyes were 
characterized as CIS-SON and likewise showed significant retinal layer thinning. The 
most pronounced thinning was present in CIS-ON eyes. 
Conclusion: Our findings indicate that retinal pathology does occur already in CIS. 
Intraretinal layer segmentation may be an easily applicable, non-invasive method for 
early detection of retinal pathology in patients unaffected by ON. 
  
Introduction 
Multiple sclerosis is an autoimmune disorder of the central nervous system that often 
manifests with optic neuritis (ON) as well as motor, sensory or cerebellar deficits in its 
earliest stage.1 Current diagnostic criteria for MS require proof of dissemination of 
lesions or attacks in time and space.2 In every day clinical practice, patients 
presenting with a first clinical event that is highly indicative of MS are often instead 
diagnosed with a clinically isolated syndrome (CIS) or “possible” MS.3 A confirmed 
diagnosis of MS is possible once additional attacks or lesions present, as is the case 
for a significant proportion of such patients.2 
In light of this, pinpointing the aspects of CIS that are most predictive for subsequent 
diagnosis with MS has high priority3 so that patients at risk can be identified. 
Diagnosing MS as early as possible and thus allowing for the widest range of 
therapeutic options, is therefore highly in the patients’ interest, in particular as 
irreversible axonal and neuronal injury is a key aspect and correlate of disability in 
MS in early disease stages.3–5 
One easily accessible means of assessing neuroaxonal damage in MS is the 
investigation of the retina. Optical coherence tomography (OCT) has shown specific 
retinal alterations in MS patients:6 The retinal nerve fiber layer (RNFL) is reduced in 
MS,7 not only in eyes with a history of ON8 but also in eyes without any previous 
clinical event of ON.9,10 Additionally, microcystic macular edema (MME) in the inner 
nuclear layer (INL) has been reported in a subset of MS patients.11 Although MME 
might not be specific to MS but instead ON dependent,12 the INL has become a key 
focus of clinical investigation of MS pathology after a postmortem histopathology 
study reported neuronal loss in the INL.13,14 
  
Additionally, retinal changes in MS do not merely reflect the visual system, but 
potentially also overall disease pathology. RNFL thinning correlates closely with brain 
atrophy,15–17 and with reduction of N-acetyl-aspartate as marker of neuroaxonal 
integrity in the visual cortex.18 
These findings suggest that the retina and, in particular, intraretinal layers may be an 
effective means of detecting subtle neuronal and axonal damage already present in 
CIS. To investigate this theory, we performed a cross-sectional study analyzing 
intraretinal changes in CIS patients. We were especially interested in retinal 
pathology in eyes that had not suffered from previous ON and therefore applied a 
rigorous classification of eyes not only on clinical assessments but also visual evoked 
potentials (VEP). 
Methods 
Study participants 
Patients were prospectively recruited from outpatient clinics at two university medical 
centers (Berlin and Düsseldorf). Inclusion criteria were clinical and paraclinical (MRI, 
CSF, EP) diagnosis of CIS suggestive of MS after relevant differential diagnoses had 
been ruled out and age between 18 and 65 years.2 Patients received MRI to exclude 
the possibility that the disease had developed into MS since first diagnosis of CIS 
Neurological disability was assessed according to the Expanded Disability Status 
Scale (EDSS).19 A history of ON was diagnosed by a treating physician and was 
cross-checked using medical records. Patients with a refractive error of more than 
±5.0 diopters or with any history of eye disease that could impact OCT 
measurements (i.e. glaucoma) were excluded. A second exclusion criterion was 
steroid therapy within 30 days prior to examination. A group of healthy controls 
  
matched by age (+/-3 years) and gender was recruited from patients’ family 
members, medical staff or volunteers. Both centres assessed the matched controls to 
their patients. To exclude potential centre effects, we additionally performed centre 
specific analysis or included centre as covariate. In these analyses centre did not 
have a significant effect (data not shown). Local ethics committees approved the 
study and all participants gave written, informed consent. 
Visual evoked potentials 
VEP were either performed during the clinical work-up or as part of the study protocol 
prior to or on the same day as the OCT assessment. We used the P100 latency 
values as a parameter to prove optic nerve conduction slowing potentially related to a 
history of ON. VEP amplitude was not analyzed because the two centers involved in 
the study performed VEP using different devices in a non-standardized manner. 
Optical coherence tomography  
Experienced operators performed OCT on undilated eyes using Heidelberg 
Spectralis SD-OCT (Heidelberg Engineering, Germany). All scans were checked for 
appropriate image quality. All participants were examined using the peripapillary ring 
scan, which measures RNFL thickness (pRNFL) around the optic nerve head in a 
circle with an angle of 12°, resulting in a diameter of 3.4 mm (example shown in 
Figure 1A). Macular volume was assessed by a custom scan comprising 61 vertical 
B-scans (each with 768 A-Scans, Automatic Real-Time (ART) = 13 frames) with a 
scanning angle of 30° x 25° focusing on the fovea. Using this scan, TMV and intra-
retinal layers thicknesses were determined within a cylinder of 6 mm diameter (Figure 
1B). 
Intraretinal layer segmentation 
  
Heidelberg Engineering provided beta software that employed a multilayer 
segmentation algorithm for macular volume scans. To analyze the inner retinal 
layers, a subset of B-scans were segmented and manually corrected by an 
experienced assessor in a blinded fashion. The multilayer analysis was performed on 
the central B-scan through the fovea and on six B-scans each in nasal and temporal 
direction. Manual correction of automatically segmented B-scans is a time consuming 
step. As a compromise we manually corrected every fourth B-scan,  thus analysing 
an area largely covering the 6 mm diameter ETDRS grid with a distance between 
adjacent B-scans of approximately 500 !m. For the combined analysis of both eyes, 
thickness maps of the left eye were mirrored vertically to match the topology of the 
right eye. The mean thickness maps within each of the study groups were calculated 
for the four innermost retinal layers: macular RNFL (mRNFL), ganglion cell layer 
(GCL), inner plexiform layer (IPL) and INL (Figure 1C). Because differentiating 
between GCL and IPL proved to be a hurdle, we used the combined thickness of 
GCL and IPL (GCIPL). Please see the supplementary data for individual analyses of 
GCL and IPL. By subtracting the group-specific mean thickness maps we produced 
spatial difference maps (Figure 3), in which negative values indicate a thinning of the 
patients’ group compared to matched healthy controls, whereas positive values 
indicated thickening. 
Statistical analysis 
Generalized estimation equation models (GEE) accounting for within-subject inter-
eye effects were used to compare OCT results between the study cohorts. For the 
subgroup analysis, only controls that were matched to the respective CIS patients’ 
eyes (NON, SON, ON) were used. Correlations between VEP and OCT results were 
performed by linear regression. All statistical analyses were performed and all figures 
  
were created using R version 2.15.0. Statistical significance was established at P < 
0.05. 
Results 
Study participants 
45 patients (Berlin 29, Düsseldorf 16) were enrolled and compared to matched 
healthy controls (Berlin 29, Düsseldorf 16). All patients were diagnosed with CIS at 
the time of OCT examination and diagnosis and non-progression towards MS was 
confirmed by means of MRI. 17 patients had unilateral optic neuritis (7 on the right, 
10 on the left eye), 14 patients presented with spinal cord symptoms. 6 patients 
experienced relapses with findings suggestive of infratentorial brain lesions, in 7 
patients supratentorial signs were found, and one patient exhibited both 
supratentorial and spinal clinical signs. Examination of one patient’s eye did not pass 
the quality criteria due to image artifacts and was excluded. Demographic and clinical 
data are summarized in Table 1.  
ON classification according to VEP latency and correlation to standard OCT results 
As a clinical diagnosis of ON may have been missed by patients or physicians, we 
created another category of subclinical (or suspected) ON in eyes without a clinical 
ON history, as assessed by VEP. In addition to the group of confirmed ON eyes (CIS-
ON), we defined a group of suspected ON eyes (CIS-SON), defined as eyes with 
prolonged P100 latency of over 115 ms but, as stated above, without a clinical history 
of ON. The latter value of a 115 ms limit for normal eyes is in accordance with 
literature20 and proved an effective means of distinguishing between eyes diagnosed 
with ON and unaffected eyes (Figure 2A and 2B). In total, seven eyes were classified 
as CIS-SON. Both eyes of two patients were classified as suspected ON and all other 
  
CIS-SON eyes were contralateral to CIS-ON eyes. Figure 2A shows the correlation 
between P100 latencies and pRNFL thickness, while Figure 2B is a graph of the 
relationship between the TMV and the VEP results. Linear regression showed 
significant correlation between pRNFL and P100 VEP latencies in all CIS eyes (R2 = 
0.243, P < 0.001) and in CIS-NON eyes (R2 = 0.065, P = 0.039) but not in CIS-SON 
and CIS-ON eyes. Similarly, TMV correlated significantly to P100 latencies for all CIS 
eyes (R2 = 0.124, P < 0.001), but not for the other subgroups. 
pRNFL and TMV comparison 
When compared to the corresponding age- and sex-matched controls, pRNFL 
thickness was reduced in CIS-ON (P < 0.001) and CIS-SON (P = 0.014) but not in 
CIS-NON eyes (P = 0.636) (Figure 2C). Analysis of macular scans revealed 
significant TMV reduction in CIS-ON eyes (P < 0.001) and, importantly, also in CIS-
NON eyes (P = 0.031) versus controls (Figure 2D). TMV reduction in the 7 CIS-SON 
eyes was not significant. 
Intraretinal multilayer segmentation 
The mean macular thickness values for inner retinal layers (mRNFL, GCIPL, INL) of 
the different groups are summarized in Table 2. A graphical representation of the 
spatial changes of CIS patients compared to the matching controls is given in Figure 
3. 
Analysis of the central macular area (6 mm in diameter around the fovea) showed 
significant reduction in mRNFL thickness in CIS-ON eyes, but not for CIS-SON and 
CIS-NON in comparison to matched controls (Table 2). Spatial difference maps 
showed that mRNFL thinning was most prominent in close proximity to the optic 
nerve head (Figure 3A, white arrows). Here, even for CIS-NON eyes mRNFL thinning 
  
was visible very close to the optic nerve head. It should be noted that macular 
volume scans are not designed to investigate the papillary region and that this area is 
highly penetrated by blood vessels, potentially causing segmentation errors; thus, the 
mRNFL results have to be evaluated with caution. 
All patient groups showed reduced GCIPL thickness compared to the matched 
healthy controls. Spatial differences of the GCIPL were found in the perimacular 
region (Figure 3B) and statistical analysis of the GCIP confirmed that the thickness in 
this area was significantly reduced for all patient groups compared to controls (Table 
2). The thinning in CIS-ON and CIS-SON eyes was more pronounced than in the 
CIS-NON group while the spatial distribution of changes was similar. Please refer to 
the supplementary material for detailed data on the analysis of the GCL and IPL 
individually. 
Analogous to pRNFL and TMV we analysed a potential correlation between VEP 
latencies and intraretinal layer thicknesses:  mRNFL (R2 = 0.203, P < 0.001) and 
GCIP (R2 = 0.315, P < 0.001) were significantly correlated to VEP latencies 
(supplementary figure 2). There was no correlation of intraretinal layer thicknesses or 
VEP latencies with symptom onset in the CIS-NON group (supplementary figure 3). 
Discussion 
We analysed intraretinal changes in a cohort of CIS patients, which included both 
eyes with confirmed previous ON, eyes with suspected ON, and eyes without 
evidence of ON compared to age- and sex-matched healthy controls. Notably, we 
identified significant thinning of GCIPL in the eyes of CIS patients without any clinical 
history of ON or suspected previous subclinical ON as determined by VEP changes. 
A supplementary analysis using distinct GCL and IPL thicknesses localized this 
  
GCIPL thinning to the GCL in CIS-NON patients. Additionally and as expected, eyes 
with a confirmed history of ON showed an even more pronounced thinning of retinal 
layers. In contrast, INL appeared unaltered. Our data indicate that retinal neuronal 
damage can accompany CIS independently of a prior history of ON.  
Three previous studies have investigated retinal changes in CIS patients: The first 
study failed to detect pRNFL or TMV reduction in the eyes of CIS patients without 
prior ON.21 A second study reported no retinal damage in the eyes of patients with 
isolated unilateral ON.22 However, these studies were conducted before the 
introduction of spectral-domain OCT (SD-OCT), the superior spatial resolution of 
which over time-domain OCT (TD-OCT)23 allows for the investigation of intraretinal 
layers.24 Previously and in particular, in the above studies, retinal alterations may 
have simply not been detectable by TD-OCT and, more importantly, GCIPL changes 
that can only quantified using SD-OCT might be superior for detecting even subtle 
neurodegeneration in CIS over pRNFL. Peripapillary RNFL also failed to detect 
differences in our groups, suggesting that this parameter is in general less sensitive 
for detecting MS pathology than new intraretinal layer measurements like GCIPL. 
With this in mind, the failure to detect significant pRNFL alterations in our CIS-NON 
cohort may simply be a power issue. A third recent study comprising 45 CIS patients 
showed a reduction of pRNFL but not TMV using SD-OCT.25 
The present study is the first to investigate intraretinal layer changes or detect retinal 
neurodegeneration independent from ON in a larger cohort of CIS patients. A recent 
study that reported reduction of the GCIPL in MS patients with and without a history 
of ON included seven CIS patients while the remaining patients had long-standing 
diagnoses of MS, which precluded reliable assessment of retinal damage in early 
disease stages.26 Other studies have shown INL impairment (i.e. microcystic macular 
  
oedema) in MS patients with longer disease duration.11,14 Such changes were not 
detected in our CIS patients, suggesting that INL impairment might be a symptom of 
later or more severe disease stages. 
Our finding that damage to the GCIPL is detectable in CIS eyes without clinical 
history of ON and with normal VEP latency lends additional support to the 
increasingly widespread understanding of MS as both a demyelinating and 
neurodegenerative disease.27 We show that neurodegeneration is not, in fact, limited 
to advanced disease stages, in which it is considered responsible for the continuous 
progression of neurological disability, even in the absence of relapses. Instead, 
neurodegeneration can begin very early in disease development. Our data 
corroborate MRI data showing neuroaxonal damage during the very earliest MS 
stages,4,28 as well as histopathology data from brain 29 and eye13, and from 
experimental autoimmune encephalomyelitis.30,31 In line with previous investigations, 
our study provides evidence that inflammatory attacks to the optic nerve to the extent 
of a clinical or subclinical ON may not be a pre-requisite for damage to the retinal 
GCIPL.26 
Our finding that neuronal retinal damage begins during very early disease stages 
raises urgent questions, the answers to which may challenge our understanding of 
the underlying pathology and mechanisms of MS.32 Is the damage we found in the 
retina a consequence of the retrograde degeneration of retinal nerve fibers that 
occurs as a consequence of autoimmune brain inflammation in MS? If the answer is 
yes, it follows that retrograde RNFL damage would subsequently initiate a 
degenerative process in the GCL via a dying back mechanism. Indeed, the 
hypothesis that retrograde retinal neuroaxonal damage takes place both after ON as 
well as brain inflammation without clinical ON is supported by experimental animal 
  
data from intracranial optic nerve sections.33 Here, ocular pathology was shown to be 
limited to the inner retina. Evidence for inner retinal layer damage has been further 
provided by the first large scale pathological description of retinae from autopsied MS 
patients showing – apart from the anticipated extensive axonal damage - neuronal 
loss in both the GCL and the INL.13 In contrast, a recent OCT study has suggested a 
primary retinal pathology as a novel distinct subtype of MS, which would implicate 
that a dying back pathomechanism does not apply to all patients:24 The study 
identified MS patients exhibiting substantial reduction of TMV and significant thinning 
of the outer and inner nuclear layers despite normal RNFL values. The authors 
suggested that retinal pathology in this disease subtype (termed “macular thinning 
predominant”) occurs independently of optic nerve pathology and may be a harbinger 
of a more aggressive disease course. However, these findings have yet to be 
confirmed by other groups and with other OCT devices in larger cohorts.34  
Some important caveats of our study should be noted. Firstly, undetected subclinical 
ON episodes in our patient cohort may have skewed our results. However, we dealt 
with this potential cohort bias swiftly by conducting a thorough clinical assessment 
and examination of the individual patients. Additionally, each patient had to undergo 
VEP: Eyes with P100 latency suspicious for ON were classified as subclinical ON 
and not as unaffected eyes. Furthermore, all patients received MRI as proof that a 
confirmed diagnosis of MS could not yet be established. Although this approach 
cannot be guaranteed to prevent all errors in ON identification, it does ensure that the 
risk of misclassification as CIS-NON or MS is negligible and that the conclusions 
drawn from our data are valid. 
A further limitation of our study is that we could not correlate morphological data to 
functional visual measures such as low contrast letter acuity. However, we are 
  
currently addressing this aspect in an ongoing CIS study that includes Sloan charts 
as suggested by a previous study.35 The high number of statistical analyses in 
comparison to the relatively low number of patients should also be noted. As we did 
not perform a previous power calculation and since OCT parameters are related and 
thus likely correlated, we did not correct for multiple comparisons, since doing so 
would have likely caused an overcorrection. We did carefully examine our cohorts for 
a possible influence of outliers and distribution effects, finding no such effect. 
However, it is important to reproduce our findings in an independent cohort. 
Segmentation of intraretinal layers is a novel technique and no studies have been 
performed so far to better understand how segmentation-derived results relate to in-
vivo morphological changes that appear in MS (e.g. through histopathological 
studies). However, a number of recent studies have successfully applied intraretinal 
segmentation,9,14,17,26,36 and comparison of different segmentation techniques 
showed excellent reproducibility and reliability.37 We have investigated reliability of 
the novel algorithm applied in this study in a cross-center inter-rater reliability study 
on a defined set of OCT macular B-scans. Results support the excellent reliability of 
intraretinal segmentation reported by others,37 with the exception that no 
histopathological correlation has been performed so far (publication in preparation). 
However, GCL and IPL are still difficult to differentiate in OCT scans and therefore 
we based our study results mostly on the combined layer of both (GCIPL) and 
present individual layer analyses as supplementary data only.  
Of note is the large amount of eyes that were classified as suspected ON (n = 7) in 
comparison to the number of eyes with definite clinical ON (n = 16). Retinal layer 
thinning in these eyes was in between NON and ON eyes, further supporting the 
notion that optic nerve inflammation is not a yes or no event. Instead, substantial 
  
damage might be caused by optic nerve inflammation before clinical visibility in form 
of an apparent clinical ON might be established. As our cohort comprised only 
patients with CIS, failure to detect subclinical ON potentially might compromise the 
discrimination between CIS patients and patients who already have definite MS. 
Clearly, detection of subclinical alterations in visual and other functional systems 
urgently needs improvement. Our study did not investigate the discriminatory 
properties of OCT and VEP between CIS and MS patients, and consequently, this 
question must be addressed by a future study. 
In summary, our study shows that retinal neurodegeneration is already detectable in 
CIS patients and is dependent but importantly also independent of clinical relapses 
(i.e. ON). Accordingly, irreversible neuronal damage in MS might be much more 
prevalent than previously thought. Long-term follow-up of our study patients, who 
exhibited very early substantial and presumably irreversible neuroaxonal damage, is 
vital to ascertain diagnosis in patients likely to develop MS as early as possible. 
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Figures 
Figure 1: Examples of regions analyzed in OCT. 
 
A) Scanning laser ophthalmoscopy image showing the region of the peripapillary ring 
scan (green); B) Scanning laser ophthalmoscopy image of the macular scan with the 
blue circle indicating the area for total macular volume and intraretinal layer thickness 
determination; C) 3D reconstruction of a macular volume scan, depicting the 
identified intraretinal layers. 
  
Abbreviations: RNFL = retinal nerve fiber layer; GCL = ganglion cell layer; IPL = inner 
plexiform layer; INL = inner nuclear layer; OPL = outer plexiform layer; ONL = outer 
nuclear layer; ELM=external limiting membrane; IS/OS = inner segments / outer 
segments; RPE = retinal pigment epithelium. 
 
Figure 2: VEP and standard OCT results. 
 
Scatterplots showing the relationship of the VEP P100 latencies with A) peripapillary 
RNFL (pRNFL) and B) total macular volume. The red dashed line at 115 ms indicates 
the threshold between CIS-NON and CIS-SON eyes. The black line is the result of 
the linear regression including all CIS eyes with the standard error given as gray 
shadow. Comparison of C) peripapillary RNFL thickness and D) total macular volume 
  
between the different CIS groups and the matching controls. Significant differences 
are marked with * (P<0.05), ** (P<0.01) and *** (P<0.001). 
Abbreviations: HC = healthy control eyes; CIS-NON = patient eyes without history of 
optic neuritis and VEP P100 <= 115 ms; CIS-SON = eyes with VEP P100 latency > 
115 ms but no ON diagnosis; CIS-ON = patient eyes with clinical ON diagnosis. 
 
Figure 3: Spatial analysis of changes in CIS eyes versus healthy control eyes. 
 
A) Changes in RNFL thickness between CIS patients and the corresponding group of 
age- and sex-matched healthy controls. Patients were stratified by history of ON: no 
  
history of ON (NON), suspected ON (SON) or clinically diagnosed ON. Reduction in 
RNFL thickness was evident near the optic nerve head (white arrows) in all groups 
but was more pronounced in SON and ON eyes. B) Thickness changes in the GCIPL 
were identified in the perimacular region and were most evident in CIS-ON eyes. 
Significant thinning of the GCIPL in CIS-NON eyes compared to the matching 
controls were found in the perimacular area (P = 0.027). C) No group showed 
significant changes in the INL. 
Abbreviations: CIS = clinically isolated syndrome; RNFL = retinal nerve fiber layer; 
GCIPL = combined ganglion cell and inner plexiform layer; INL = inner nuclear layer. 
 
 
